Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Senior Vice President, Finance | October 08, 2026 | October 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 62,284.242 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 6,000 · Balance 68,284.242 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. Row 2 · 2026-10-08 · Sale · Disposed 6,000 · Balance 62,284.242 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.35 · Expires 2026-12-07 | Direct | 0 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 6,000 · Balance 0 F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026. F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The option exercise and sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on March 12, 2026.
F2: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2021 Filed Mar 18, 2021 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,000 | $10.81 | $21,620.00 |
DisclosureSEC source: 0001209191-21-021585 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,520 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-21-021585 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 Underlying: Common Stock · 1,520 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,520 | $73.28 | $111,385.60 |
DisclosureSEC source: 0001209191-21-021585 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,181 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $73.03 to $73.50, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. Read SEC document |
| March 15, 2021 Filed Mar 18, 2021 00:03 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,520 | $10.81 | $16,431.20 |
DisclosureSEC source: 0001209191-21-021585 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,701 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-20-058828 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,820 Underlying: Common Stock · 3,000 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,000 | $63.81 | $191,430.00 |
DisclosureSEC source: 0001209191-20-058828 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,181 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 22:37 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,000 | $10.81 | $32,430.00 |
DisclosureSEC source: 0001209191-20-058828 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-20-051034 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,820 Underlying: Common Stock · 3,000 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,000 | $60.34 | $181,020.00 |
DisclosureSEC source: 0001209191-20-051034 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,181 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.975 to $60.88, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:10 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,000 | $10.81 | $32,430.00 |
DisclosureSEC source: 0001209191-20-051034 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,181 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,180 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-20-046610 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,180 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 8,180 | $60.50 | $494,890.00 |
DisclosureSEC source: 0001209191-20-046610 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,181 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.495 to $60.53, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes 548 shares of common stock acquired under the issuer's employee stock purchase plan in June 2020. Read SEC document |
| August 11, 2020 Filed Aug 13, 2020 20:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 8,180 | $10.34 | $84,581.20 |
DisclosureSEC source: 0001209191-20-046610 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-20-039978 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,180 Underlying: Common Stock · 6,000 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $50.34 | $100,680.00 |
DisclosureSEC source: 0001209191-20-039978 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,633 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $49.34 | $98,680.00 |
DisclosureSEC source: 0001209191-20-039978 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,633 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $48.72 | $97,440.00 |
DisclosureSEC source: 0001209191-20-039978 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,633 F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 29, 2020 Filed Jul 2, 2020 01:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 6,000 | $10.34 | $62,040.00 |
DisclosureSEC source: 0001209191-20-039978 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,633 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036051 · doc4.xml · derivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:33 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036051 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,633 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2021, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 01:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,752 | $48.37 | $84,744.24 |
DisclosureSEC source: 0001209191-20-035174 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,833 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $48.37 to $48.45, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 04, 2020 Filed Jun 9, 2020 01:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 879 | $46.33 | $40,724.95 |
DisclosureSEC source: 0001209191-20-035174 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,585 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| May 21, 2020 Filed May 21, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-20-031513 · doc4.xml · derivative · entry 6 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,180 Underlying: Common Stock · 2,000 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| May 21, 2020 Filed May 21, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $45.26 | $90,520.00 |
DisclosureSEC source: 0001209191-20-031513 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.03 to $45.49, inclusive. Read SEC document |
| May 21, 2020 Filed May 21, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,000 | $10.34 | $20,680.00 |
DisclosureSEC source: 0001209191-20-031513 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 19, 2020 Filed May 21, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,000 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-20-031513 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,180 Underlying: Common Stock · 2,000 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| May 19, 2020 Filed May 21, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 2,000 | $42.81 | $85,620.00 |
DisclosureSEC source: 0001209191-20-031513 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.79 to $42.85, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2. Read SEC document |
| May 19, 2020 Filed May 21, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,000 | $10.34 | $20,680.00 |
DisclosureSEC source: 0001209191-20-031513 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008769 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,820 Underlying: Common Stock · 3,000 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $49.81 | $49,810.00 |
DisclosureSEC source: 0001209191-20-008769 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $48.81 | $48,810.00 |
DisclosureSEC source: 0001209191-20-008769 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,464 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $47.81 | $47,810.00 |
DisclosureSEC source: 0001209191-20-008769 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,464 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:41 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 3,000 | $10.81 | $32,430.00 |
DisclosureSEC source: 0001209191-20-008769 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 170 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008074 · doc4.xml · derivative · entry 6 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,820 Underlying: Common Stock · 170 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 170 | $46.81 | $7,957.70 |
DisclosureSEC source: 0001209191-20-008074 · doc4.xml · nonDerivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 07, 2020 Filed Feb 10, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 170 | $10.81 | $1,837.70 |
DisclosureSEC source: 0001209191-20-008074 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 830 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-20-008074 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,990 Underlying: Common Stock · 830 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 830 | $46.81 | $38,852.30 |
DisclosureSEC source: 0001209191-20-008074 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| February 06, 2020 Filed Feb 10, 2020 23:19 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 830 | $10.81 | $8,972.30 |
DisclosureSEC source: 0001209191-20-008074 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,294 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-19-061926 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,820 Underlying: Common Stock · 1,000 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,000 | $45.92 | $45,920.00 |
DisclosureSEC source: 0001209191-19-061926 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| December 23, 2019 Filed Dec 26, 2019 21:08 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,000 | $10.81 | $10,810.00 |
DisclosureSEC source: 0001209191-19-061926 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,464 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| November 20, 2019 Filed Nov 23, 2019 00:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,000 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-19-057869 · doc4.xml · derivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,820 Underlying: Common Stock · 1,000 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| November 20, 2019 Filed Nov 23, 2019 00:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 1,176 | $44.14 | $51,908.64 |
DisclosureSEC source: 0001209191-19-057869 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,464 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.61 to $44.27, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 20, 2019 Filed Nov 23, 2019 00:28 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,000 | $10.81 | $10,810.00 |
DisclosureSEC source: 0001209191-19-057869 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 180 | $0.00 Strike: $10.81 | $0.00 |
DisclosureSEC source: 0001209191-19-056093 · doc4.xml · derivative · entry 5 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,820 Underlying: Common Stock · 180 shares Expires 2022-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on June 5, 2013 and vested as to the remaining shares in successive equal monthly installments for the subsequent 36 months. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,820 | $0.00 Strike: $10.34 | $0.00 |
DisclosureSEC source: 0001209191-19-056093 · doc4.xml · derivative · entry 4 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,180 Underlying: Common Stock · 4,820 shares Expires 2021-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested and became exercisable as to 25% of the option shares on May 2, 2012 and vested as to the remaining shares in successive equal monthly installments over the subsequent 36 months. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 5,000 | $43.59 | $217,950.00 |
DisclosureSEC source: 0001209191-19-056093 · doc4.xml · nonDerivative · entry 3 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,640 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.96, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 180 | $10.81 | $1,945.80 |
DisclosureSEC source: 0001209191-19-056093 · doc4.xml · nonDerivative · entry 2 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,640 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 11, 2019 Filed Nov 12, 2019 22:12 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 4,820 | $10.34 | $49,838.80 |
DisclosureSEC source: 0001209191-19-056093 · doc4.xml · nonDerivative · entry 1 Riker Lauren Bullaro · CIK 0001545439 · Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 598 shares of common stock acquired under the issuer's employee stock purchase plan in June 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.